首頁 > 市場調查報告書 > 製藥

循環系統

市場調查報告書

商品編碼

1448540

全球血栓藥物市場研究報告 - 2024 年至 2032 年產業分析、規模、佔有率、成長、趨勢與預測

Global Thrombosis Drugs Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

出版日期: 2024年02月01日 | 出版商:

Value Market Research | 英文 240 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

全球血栓藥物市場需求預計將從 2023 年的 313.7 億美元增至 2032 年的近 589 億美元，2024-2032 年研究期間複合CAGR為 7.25%。

血栓藥物是用於預防或治療血栓形成（血栓）的藥物。這些藥物，包括抗凝血劑和抗血小板劑，對於治療深部靜脈栓塞和肺栓塞等疾病以及預防某些心血管疾病患者的中風至關重要。

市場動態

血栓藥物市場的促進因素包括血栓性疾病盛行率的增加、人口老化以及肥胖和久坐行為等與生活方式相關的危險因子。血栓藥物，包括抗凝血劑和抗血小板劑，對於預防和治療深部靜脈栓塞、肺栓塞和中風等疾病至關重要。心血管疾病盛行率的上升以及外科和醫療環境中有效血栓預防的需求促進了市場的成長。此外，藥物配方的進步和安全性提高的新型抗凝血劑的開發刺激了市場需求。人們對血栓形成危險因子的認知不斷增強以及早期介入的重要性進一步推動了市場的發展。對血栓管理的監管支持和直介面服抗凝血劑（DOAC）的引入有助於血栓藥物治療的持續發展。此外，正在進行的以個人化醫療和標靶治療為重點的研發活動旨在提高血栓藥物的療效和安全性，從而塑造市場軌跡。

研究報告涵蓋波特五力模型、市場吸引力分析和價值鏈分析。這些工具有助於清晰地了解行業結構並評估全球範圍內的競爭吸引力。此外，這些工具也對全球血栓藥物市場的各個細分市場進行了包容性評估。血栓藥物產業的成長和趨勢為本研究提供了整體方法。

市場區隔

血栓藥物市場報告的這一部分提供了國家和區域層面細分市場的詳細資料，從而幫助戰略家確定相應產品或服務的目標人群以及即將到來的機會。

按藥物類別

Xa 因子抑制劑
低分子肝素
P2Y12 血小板抑制劑
其他

按指示

肺栓塞
心房震顫
深層靜脈栓塞
其他

按配銷通路

醫院藥房
零售藥局
網路藥局

區域分析

本節涵蓋區域前景，重點介紹北美、歐洲、亞太地區、拉丁美洲以及中東和非洲血栓藥物市場當前和未來的需求。此外，該報告重點關注所有主要地區各個應用領域的需求、估計和預測。

該研究報告還涵蓋了市場主要參與者的全面概況以及對全球競爭格局的深入了解。血栓藥物市場的主要參與者包括葛蘭素史克公司、百特國際公司、強生公司、賽諾菲公司、百時美施貴寶公司、阿斯利康公司、拜耳公司、阿斯彭製藥控股有限公司、勃林格殷格翰公司、輝瑞公司。對競爭格局的整體看法，包括各種策略發展，例如關鍵併購、未來能力、合作夥伴關係、財務概況、合作、新產品開發、新產品發布和其他發展。

如果您有任何客製化要求，請寫信給我們。我們的研究團隊可以根據您的需求提供客製化報告。

區域展望
介紹
北美銷售分析
- 概覽、歷史與預測資料銷售分析
- 北美按細分市場銷售分析
- 北美按國家銷售分析
- 美國銷售分析
- 加拿大銷售分析
- 墨西哥銷售分析
歐洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 歐洲按細分市場銷售分析
- 歐洲按國家銷售分析
- 英國銷售分析
- 法國銷售分析
- 德國銷售分析
- 義大利銷售分析
- 俄羅斯銷售分析
- 歐洲其他地區銷售分析
亞太地區銷售分析
- 概覽、歷史與預測資料銷售分析
- 亞太地區按細分市場銷售分析
- 亞太地區國家/地區銷售分析
- 中國銷售分析
- 印度銷售分析
- 日本銷售分析
- 韓國銷售分析
- 澳洲銷售分析
- 東南亞銷售分析
- 亞太地區其他地區銷售分析
拉丁美洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 拉丁美洲按細分市場銷售分析
- 拉丁美洲按國家銷售分析
- 巴西銷售分析
- 阿根廷銷售分析
- 秘魯銷售分析
- 智利銷售分析
- 拉丁美洲其他地區銷售分析
中東和非洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 中東和非洲按細分市場銷售分析
- 中東和非洲國家銷售分析
- 沙烏地阿拉伯銷售分析
- 阿拉伯聯合大公國銷售分析
- 以色列銷售分析
- 南非銷售分析
- 中東其他地區和非洲銷售分析

第 9 章：血栓藥物公司的競爭格局

血栓藥物市場競爭
夥伴關係/協作/協議
併購
新產品發布
其他發展

第 10 章：公司簡介

公司股份分析
市場集中度
GSK plc

公司簡介
公司收入
產品
最近的發展

Baxter International Inc.

公司簡介
公司收入
產品
最近的發展

Johnson & Johnson

公司簡介
公司收入
產品
最近的發展

Sanofi

公司簡介
公司收入
產品
最近的發展

Bristol-Myers Squibb Company

公司簡介
公司收入
產品
最近的發展

AstraZeneca plc

公司簡介
公司收入
產品
最近的發展

Bayer AG

公司簡介
公司收入
產品
最近的發展

Aspen Pharmacare Holdings Limited

公司簡介
公司收入
產品
最近的發展

Boehringer Ingelheim GmbH Pfizer Inc.

公司簡介
公司收入
產品
最近的發展

注意 - 在公司概況中，財務詳細資訊和近期發展視情況而定，或者如果是私人公司，則可能不包括在內

簡介目錄圖表

Product Code: VMR112113806

The global demand for Thrombosis Drugs Market is presumed to reach the market size of nearly USD 58.9 BN by 2032 from USD 31.37 BN in 2023 with a CAGR of 7.25% under the study period 2024 - 2032.

Thrombosis drugs are medications used to prevent or treat thrombosis, which is the formation of blood clots. These drugs, including anticoagulants and antiplatelet agents, are essential in managing conditions like deep vein thrombosis and pulmonary embolism and preventing stroke in patients with certain cardiovascular diseases.

MARKET DYNAMICS

The thrombosis drugs market is driven by factors such as the increasing prevalence of thrombotic disorders, aging populations, and lifestyle-related risk factors such as obesity and sedentary behavior. Thrombosis drugs, including anticoagulants and antiplatelet agents, are essential in preventing and treating conditions like deep vein thrombosis, pulmonary embolism, and stroke. The rising prevalence of cardiovascular diseases and the need for effective thromboprophylaxis in surgical and medical settings contribute to market growth. Additionally, advancements in drug formulations and the development of novel anticoagulants with improved safety profiles stimulate market demand. The expanding awareness of thrombosis risk factors and the importance of early intervention further fuel the market. Regulatory support for thrombosis management and the introduction of direct oral anticoagulants (DOACs) contribute to the evolving landscape of thrombosis drug therapies. Moreover, ongoing research and development activities focused on personalized medicine and targeted therapies aim to enhance the efficacy and safety of thrombosis drugs, shaping the market's trajectory.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of thrombosis drugs. The growth and trends of thrombosis drugs industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the thrombosis drugs market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Drug Class

Factor Xa Inhibitor
Low Molecular Weight Heparin
P2Y12 Platelet Inhibitor
Others

By Indication

Pulmonary Embolism
Atrial Fibrillation
Deep Vein Thrombosis
Others

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Thrombosis Drugs market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Thrombosis Drugs market include GSK plc, Baxter International Inc., Johnson & Johnson, Sanofi, Bristol-Myers Squibb Company, AstraZeneca plc, Bayer AG, Aspen Pharmacare Holdings Limited, Boehringer Ingelheim GmbH Pfizer, Inc. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1 . PREFACE

1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3 . THROMBOSIS DRUGS - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Drug Class
- 3.7.2 Market Attractiveness Analysis By Indication
- 3.7.3 Market Attractiveness Analysis By Distribution Channel
- 3.7.4 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend

5 . GLOBAL THROMBOSIS DRUGS MARKET ANALYSIS BY DRUG CLASS

5.1 Overview by Drug Class
5.2 Historical and Forecast Data
5.3 Analysis by Drug Class
5.4 Factor Xa Inhibitor Historic and Forecast Sales by Regions
5.5 Low Molecular Weight Heparin Historic and Forecast Sales by Regions
5.6 P2Y12 Platelet Inhibitor Historic and Forecast Sales by Regions
5.7 Others Historic and Forecast Sales by Regions

6 . GLOBAL THROMBOSIS DRUGS MARKET ANALYSIS BY INDICATION

6.1 Overview by Indication
6.2 Historical and Forecast Data
6.3 Analysis by Indication
6.4 Pulmonary Embolism Historic and Forecast Sales by Regions
6.5 Atrial Fibrillation Historic and Forecast Sales by Regions
6.6 Deep Vein Thrombosis Historic and Forecast Sales by Regions
6.7 Others Historic and Forecast Sales by Regions

7 . GLOBAL THROMBOSIS DRUGS MARKET ANALYSIS BY DISTRIBUTION CHANNEL

7.1 Overview by Distribution Channel
7.2 Historical and Forecast Data
7.3 Analysis by Distribution Channel
7.4 Hospital Pharmacies Historic and Forecast Sales by Regions
7.5 Retail Pharmacies Historic and Forecast Sales by Regions
7.6 Online Pharmacies Historic and Forecast Sales by Regions

8 . GLOBAL THROMBOSIS DRUGS MARKET ANALYSIS BY GEOGRAPHY

8.1. Regional Outlook
8.2. Introduction
8.3. North America Sales Analysis
- 8.3.1. Overview, Historic and Forecast Data Sales Analysis
- 8.3.2. North America By Segment Sales Analysis
- 8.3.3. North America By Country Sales Analysis
- 8.3.4. United State Sales Analysis
- 8.3.5. Canada Sales Analysis
- 8.3.6. Mexico Sales Analysis
8.4. Europe Sales Analysis
- 8.4.1. Overview, Historic and Forecast Data Sales Analysis
- 8.4.2. Europe by Segment Sales Analysis
- 8.4.3. Europe by Country Sales Analysis
- 8.4.4. United Kingdom Sales Analysis
- 8.4.5. France Sales Analysis
- 8.4.6. Germany Sales Analysis
- 8.4.7. Italy Sales Analysis
- 8.4.8. Russia Sales Analysis
- 8.4.9. Rest Of Europe Sales Analysis
8.5. Asia Pacific Sales Analysis
- 8.5.1. Overview, Historic and Forecast Data Sales Analysis
- 8.5.2. Asia Pacific by Segment Sales Analysis
- 8.5.3. Asia Pacific by Country Sales Analysis
- 8.5.4. China Sales Analysis
- 8.5.5. India Sales Analysis
- 8.5.6. Japan Sales Analysis
- 8.5.7. South Korea Sales Analysis
- 8.5.8. Australia Sales Analysis
- 8.5.9. South East Asia Sales Analysis
- 8.5.10. Rest Of Asia Pacific Sales Analysis
8.6. Latin America Sales Analysis
- 8.6.1. Overview, Historic and Forecast Data Sales Analysis
- 8.6.2. Latin America by Segment Sales Analysis
- 8.6.3. Latin America by Country Sales Analysis
- 8.6.4. Brazil Sales Analysis
- 8.6.5. Argentina Sales Analysis
- 8.6.6. Peru Sales Analysis
- 8.6.7. Chile Sales Analysis
- 8.6.8. Rest of Latin America Sales Analysis
8.7. Middle East & Africa Sales Analysis
- 8.7.1. Overview, Historic and Forecast Data Sales Analysis
- 8.7.2. Middle East & Africa by Segment Sales Analysis
- 8.7.3. Middle East & Africa by Country Sales Analysis
- 8.7.4. Saudi Arabia Sales Analysis
- 8.7.5. UAE Sales Analysis
- 8.7.6. Israel Sales Analysis
- 8.7.7. South Africa Sales Analysis
- 8.7.8. Rest Of Middle East And Africa Sales Analysis

9 . COMPETITIVE LANDSCAPE OF THE THROMBOSIS DRUGS COMPANIES

9.1. Thrombosis Drugs Market Competition
9.2. Partnership/Collaboration/Agreement
9.3. Merger And Acquisitions
9.4. New Product Launch
9.5. Other Developments

10 . COMPANY PROFILES OF THROMBOSIS DRUGS INDUSTRY

10.1. Company Share Analysis
10.2. Market Concentration Rate
10.3. GSK plc
- 10.3.1. Company Overview
- 10.3.2. Company Revenue
- 10.3.3. Products
- 10.3.4. Recent Developments
10.4. Baxter International Inc.
- 10.4.1. Company Overview
- 10.4.2. Company Revenue
- 10.4.3. Products
- 10.4.4. Recent Developments
10.5. Johnson & Johnson
- 10.5.1. Company Overview
- 10.5.2. Company Revenue
- 10.5.3. Products
- 10.5.4. Recent Developments
10.6. Sanofi
- 10.6.1. Company Overview
- 10.6.2. Company Revenue
- 10.6.3. Products
- 10.6.4. Recent Developments
10.7. Bristol-Myers Squibb Company
- 10.7.1. Company Overview
- 10.7.2. Company Revenue
- 10.7.3. Products
- 10.7.4. Recent Developments
10.8. AstraZeneca plc
- 10.8.1. Company Overview
- 10.8.2. Company Revenue
- 10.8.3. Products
- 10.8.4. Recent Developments
10.9. Bayer AG
- 10.9.1. Company Overview
- 10.9.2. Company Revenue
- 10.9.3. Products
- 10.9.4. Recent Developments
10.10. Aspen Pharmacare Holdings Limited
- 10.10.1. Company Overview
- 10.10.2. Company Revenue
- 10.10.3. Products
- 10.10.4. Recent Developments
10.11. Boehringer Ingelheim GmbH Pfizer Inc.
- 10.11.1. Company Overview
- 10.11.2. Company Revenue
- 10.11.3. Products
- 10.11.4. Recent Developments